Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Reduced progression of atherosclerosis tied to statin drugs lowering fats, protein

06.01.2005


Aggressive therapy with statins -- drugs that inhibit cholesterol synthesis -- works better than moderate statin therapy in reducing fats and proteins in the blood that have been linked to atherosclerosis, a new multi-center study concludes. Statins’ effects on both complex compounds appear beneficial in cutting patients’ cardiovascular risks.



Atherosclerosis is the progressive disease process, often called hardening of the arteries, in which blood vessels slowly narrow with brain- and heart-threatening plaque, something like rust blocking water flow in an iron pipe.

A report on the research appears in Thursday’s (Jan. 6) issue of the New England Journal of Medicine.


More than three dozen investigators from across the country participated in the research, including first author Dr. Steven E. Nissen of the Cleveland Clinic Foundation and Dr. Sidney C. Smith Jr.

A past president of the American Heart Association, Smith is professor of medicine and director of the Center for Cardiovascular Science and Medicine at the University of North Carolina at Chapel Hill School of Medicine. He also served on the steering committee of a second, closely related investigation appearing in the same issue and led by Dr. Paul M. Ridker of Harvard Medical School and others.

Scientists designed the first study to investigate the relative contributions of statins in lowering fats in blood and also C-reactive protein (CRP), the most reliable laboratory measure of systemic inflammation in the body. It involved performing ultrasound tests on 502 U.S. patients with documented coronary artery disease.

Half the patients then received 40 milligrams of pravastatin, while the rest underwent the more aggressive treatment of 80 milligrams of atorvastatin. Doctors repeated the ultrasound evaluations 18 months later.

In the group as a whole, the mean LDL cholesterol level dropped from 150.2 milligrams per deciliter to 94.5 milligrams per deciliter. Both cholesterol and C-reactive protein levels correlated with progression of patients’ disease.

"Patients with reductions in both LDL cholesterol and C-reactive protein that were greater than the median had significantly slower rates of progression than patients with reductions in both biomarkers that were less than the median," the authors wrote.

The second study involved 3,745 people. Patients who were found to have low C-reactive protein levels after treatment fared better than those with higher CRP levels, regardless of their post-therapy cholesterol level.

"Taken together, these two studies emphasize the importance of inflammation in patients with coronary heart disease and suggest that inflammatory markers such as CRP may be useful along with traditional risk factors such as LDL cholesterol in patient management," Smith said. "The question at this point is what further therapy or therapies might be most effective in such patients."

Results of prospective, randomized clinical trials could be helpful in resolving that question, he said. They also should contribute to important decisions about improving guideline recommendations.

"Patients who are on low-dose statin therapy may benefit by increases in their statin therapy," Smith said. "However, those already taking maximum doses of statin, as well as all patients with coronary heart disease, should know that smoking cessation, weight loss and exercise all are associated with improvements in CRP levels.

"These studies confirm the value of lipid lowering for patients with coronary heart disease and suggest that therapy targeted to reduce the active inflammatory state may carry additional benefits," he said.

Dr. Michael R. Ehrenstein and colleagues in the department of medicine at University College in London wrote an accompanying editorial.

The two articles confirm that reducing the inflammatory component of cardiovascular disease through use of statin therapy improves clinical outcomes independently of the reduction in serum cholesterol levels, the authors wrote.

"…The list of disorders for which statins might prove beneficial is growing and now extends from multiple sclerosis and neurodegenerative disorders to rheumatoid arthritis and systemic lupus erythematosus," they wrote.

David Williamson | EurekAlert!
Further information:
http://www.unc.edu

More articles from Health and Medicine:

nachricht PET imaging tracks Zika virus infection, disease progression in mouse model
20.09.2017 | US Army Medical Research Institute of Infectious Diseases

nachricht 'Exciting' discovery on path to develop new type of vaccine to treat global viruses
18.09.2017 | University of Southampton

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

Im Focus: Fast, convenient & standardized: New lab innovation for automated tissue engineering & drug

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...

Im Focus: Silencing bacteria

HZI researchers pave the way for new agents that render hospital pathogens mute

Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Molecular Force Sensors

20.09.2017 | Life Sciences

Producing electricity during flight

20.09.2017 | Power and Electrical Engineering

Tiny lasers from a gallery of whispers

20.09.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>